These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28841278)

  • 1. Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X
    Wilkinson SM; Barron ML; O'Brien-Brown J; Janssen B; Stokes L; Werry EL; Chishty M; Skarratt KK; Ong JA; Hibbs DE; Vugts DJ; Fuller S; Windhorst AD; Kassiou M
    ACS Chem Neurosci; 2017 Nov; 8(11):2374-2380. PubMed ID: 28841278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor.
    Subramanyam C; Duplantier AJ; Dombroski MA; Chang SP; Gabel CA; Whitney-Pickett C; Perregaux DG; Labasi JM; Yoon K; Shepard RM; Fisher M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5475-9. PubMed ID: 21782426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists.
    T Pournara D; Durner A; Kritsi E; Papakostas A; Zoumpoulakis P; Nicke A; Koufaki M
    ChemMedChem; 2020 Dec; 15(24):2530-2543. PubMed ID: 32964578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.
    Letavic MA; Savall BM; Allison BD; Aluisio L; Andres JI; De Angelis M; Ao H; Beauchamp DA; Bonaventure P; Bryant S; Carruthers NI; Ceusters M; Coe KJ; Dvorak CA; Fraser IC; Gelin CF; Koudriakova T; Liang J; Lord B; Lovenberg TW; Otieno MA; Schoetens F; Swanson DM; Wang Q; Wickenden AD; Bhattacharya A
    J Med Chem; 2017 Jun; 60(11):4559-4572. PubMed ID: 28493698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists.
    Ameriks MK; Ao H; Carruthers NI; Lord B; Ravula S; Rech JC; Savall BM; Wall JL; Wang Q; Bhattacharya A; Letavic MA
    Bioorg Med Chem Lett; 2016 Jan; 26(2):257-261. PubMed ID: 26707399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X
    O'Brien-Brown J; Jackson A; Reekie TA; Barron ML; Werry EL; Schiavini P; McDonnell M; Munoz L; Wilkinson S; Noll B; Wang S; Kassiou M
    Eur J Med Chem; 2017 Apr; 130():433-439. PubMed ID: 28279849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120.
    Allsopp RC; Dayl S; Schmid R; Evans RJ
    Sci Rep; 2017 Apr; 7(1):725. PubMed ID: 28389651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape from adamantane: Scaffold optimization of novel P2X7 antagonists featuring complex polycycles.
    Barniol-Xicota M; Kwak SH; Lee SD; Caseley E; Valverde E; Jiang LH; Kim YC; Vázquez S
    Bioorg Med Chem Lett; 2017 Feb; 27(4):759-763. PubMed ID: 28126517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors.
    Furber M; Alcaraz L; Bent JE; Beyerbach A; Bowers K; Braddock M; Caffrey MV; Cladingboel D; Collington J; Donald DK; Fagura M; Ince F; Kinchin EC; Laurent C; Lawson M; Luker TJ; Mortimore MM; Pimm AD; Riley RJ; Roberts N; Robertson M; Theaker J; Thorne PV; Weaver R; Webborn P; Willis P
    J Med Chem; 2007 Nov; 50(24):5882-5. PubMed ID: 17963373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist.
    Chen X; Pierce B; Naing W; Grapperhaus ML; Phillion DP
    Bioorg Med Chem Lett; 2010 May; 20(10):3107-11. PubMed ID: 20392639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway.
    Fan J; Zhao RQ; Parro C; Zhao W; Chou HY; Robert J; Deeb TZ; Raynoschek C; Barichievy S; Engkvist O; Maresca M; Hicks R; Meuller J; Moss SJ; Brandon NJ; Wood MW; Kulic I; Wellington CL
    J Lipid Res; 2018 May; 59(5):830-842. PubMed ID: 29563219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD-9056, a P2X7 receptor inhibitor, suppresses ATP-induced melanogenesis.
    Kim JY; Lee EJ; Seong YJ; Ahn Y; Park S; Lee J; Oh SH
    J Dermatol Sci; 2020 Dec; 100(3):227-229. PubMed ID: 33051087
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists.
    Rudolph DA; Alcazar J; Ameriks MK; Anton AB; Ao H; Bonaventure P; Carruthers NI; Chrovian CC; De Angelis M; Lord B; Rech JC; Wang Q; Bhattacharya A; Andres JI; Letavic MA
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3157-63. PubMed ID: 26099534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.
    Duplantier AJ; Dombroski MA; Subramanyam C; Beaulieu AM; Chang SP; Gabel CA; Jordan C; Kalgutkar AS; Kraus KG; Labasi JM; Mussari C; Perregaux DG; Shepard R; Taylor TJ; Trevena KA; Whitney-Pickett C; Yoon K
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3708-11. PubMed ID: 21565499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists.
    Park JH; Lee GE; Lee SD; Ko H; Kim YC
    Eur J Med Chem; 2015 Dec; 106():180-93. PubMed ID: 26547056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.
    Swanson DM; Savall BM; Coe KJ; Schoetens F; Koudriakova T; Skaptason J; Wall J; Rech J; Deng X; De Angelis M; Everson A; Lord B; Wang Q; Ao H; Scott B; Sepassi K; Lovenberg TW; Carruthers NI; Bhattacharya A; Letavic MA
    J Med Chem; 2016 Sep; 59(18):8535-48. PubMed ID: 27548392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the allosteric P2X
    Janssen B; Vugts DJ; Wilkinson SM; Ory D; Chalon S; Hoozemans JJM; Schuit RC; Beaino W; Kooijman EJM; van den Hoek J; Chishty M; Doméné A; Van der Perren A; Villa A; Maggi A; Molenaar GT; Funke U; Shevchenko RV; Baekelandt V; Bormans G; Lammertsma AA; Kassiou M; Windhorst AD
    Sci Rep; 2018 Apr; 8(1):6580. PubMed ID: 29700413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of second-generation P2X3 antagonists for treatment of pain.
    Ginnetti AT; Paone DV; Stauffer SR; Potteiger CM; Shaw AW; Deng J; Mulhearn JJ; Nguyen DN; Segerdell C; Anquandah J; Calamari A; Cheng G; Leitl MD; Liang A; Moore E; Panigel J; Urban M; Wang J; Fillgrove K; Tang C; Cook S; Kane S; Salvatore CA; Graham SL; Burgey CS
    Bioorg Med Chem Lett; 2018 May; 28(8):1392-1396. PubMed ID: 29548573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploratory study of oxatomide derivatives with high P2X
    Yamagiwa N; Komine M; Hanaoka F; Nobuta T; Yoshida K; Ito M; Matsuoka I
    Bioorg Med Chem Lett; 2022 Dec; 77():129035. PubMed ID: 36283612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2X7 receptor antagonism: Implications in diabetic retinopathy.
    Platania CBM; Giurdanella G; Di Paola L; Leggio GM; Drago F; Salomone S; Bucolo C
    Biochem Pharmacol; 2017 Aug; 138():130-139. PubMed ID: 28479300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.